D-DIF
CI-CY | D-DIF | DIG-DY | E

Product #

Image

Product Name

Biochem/physiol Actions

Gene Symbol (ID)

Add to Cart
SML1422 CCG-203971 ≥98% (HPLC) CCG-203971 is an inhibitor of the Rho/MKL1/SRF transcriptional pathway, which has been shown to play a role in metastasis of melanoma and breast cancer and clinically associated with castration-resistant prostate cancer. CCG-203971 is a second-generation analog of CCG-1423 (SML0987) with an IC50 of 4.2 μM vs 1 μM for CCG-1423, but less cytotoxicity. In mouse studies, CCG-203971 inhibited invasion of PC-3 prostate cancer cells and was well tolerated up to doses of 100 mg/kg IP over 5 days.

The Rho/MRTF/SRF pathway has also been shown to be involved in multiple types of solid organ fibrosis. CCG-203971 repressed both matrix-stiffness and TGF-β-mediated fibrogenesis in human colonic myofibroblasts and showed antifibrotic activity in a murine model of skin injury and in pulmonary fibrosis lung fibroblasts.
  
    • SML1052   2-D08 ≥98% (HPLC) 2-D08 is a potent and cell-permeable inhibitor of sumoylation that block the transfer of SUMO (small ubiquitin-like modifier) from the E2 enzyme (Ubc9) thioester conjugate to the substrate.
    		  
    • D5321 D36 hydrate ≥98% (HPLC) D36 is an androgen receptor (AR) allosteric antagonist with inverse agonist properties. D36 inhibits both wild-type and agonist-induced AR activity and antagonized AR in a hormone-refractory model.
    		  
    • SML2256 D3-βArr ≥98% (HPLC) D3-βArr is a positive allosteric modulator of TSHR (thyrotropin receptor) for β-Arr 1-mediated signaling that initiates translocation of β-Arr 1 by direct TSHR activation, while showing no agonistic effect on cAMP production. D3-βarr is a positive allosteric modulator for TSH-enhanced osteoblast differentiation.
    		  
    • D5571   D3T ≥98% (NMR) D3T is a cancer chemopreventive agent.
    		  
    • D1944 D4476 ≥98% (HPLC), solid D4476 is a potent, selective ATP-competitive inhibitor of CK1 (casein kinase 1).
    D4476 may prevent or enhance apoptosis. It triggers tumor suppressor p53 and impairs transcription factor E2F-1.
    		  
    • SML2370 Dabigatran ≥95% (HPLC) Dabigatran is a nonpeptide direct thrombin inhibitor. It is an anticoagulant that functions by directly inhibiting both free and fibrin-bound thrombin. Dabigatron has been shown to prevent strokes in those with atrial fibrillation not caused by heart valve issues.
    		  
    • SML2351 Dabigatran etexilate ≥98% (HPLC) Dabigatran etexilate is a prodrug of dabigatran, a nonpeptide direct thrombin inhibitor. Dabigatron is an anticoagulant that functions by directly inhibiting both free and fibrin-bound thrombin. Dabigatron has been shown to prevent strokes in those with atrial fibrillation not caused by heart valve issues.
    		  
    • SML0736   Dafadine A ≥98% (HPLC) Dafadine A is a selective inhibitor of C. elegans DAF-9 cytochrome P450, a key regulator of dauer formation, developmental timing and longevity. C. elegans has four life stages. In harsh environmental conditions, nematodes can convert to the L3 stage, known as the ""non-aging"" dauer stage, in which development ceases until improved conditions are sensed. Dafadine A can induce dauer formation and increased longevity in wild-type worms raised in nonstressful conditions. Dafadine A is the only inhibitor known to robustly inhibit DAF-9 in wild-type worms. It does not inhibit DAF-12 activity. Dafadine is active in mammalian systems, inhibiting CYP27A1, the mammalian functional ortholog of DAF-9 that oxidizes 4-cholesten-3-one to make 26-hydroxy-4-cholesten-3-one and Δ4-dafachronic acid, without inhibiting other sterol- and oxysterol-metabolizing P450s such as CYP7A1 or CYP7B1.
    		  
    • D1821 DAF-FM ≥98% (HPLC) DAF-FM is a highly sensitive, photo-stable fluorescent probe for the detection of nitric oxide (NO). DAF-2 is the original compound and is widely used, but DAF-FM is more sensitive to nitric oxide (NO) compared with DAF-2. DAF-FM is more photo-stable and less pH sensitive than DAF-2. DAF-FM is not quite as cell-permeable as the diacetate derivative, DAF-FM, but it does not need to be activated by cytosolic enzymes.
    		  
    • D1946 DAF-FM DA ≥98% (HPLC) DAF-FM DA is a cell-permeable fluorescent probe for the detection of nitric oxide (NO). DAF-2 is the original compound and is widely used, but DAF-FM and DAF-FM DA are more sensitive to nitric oxide (NO) compared with DAF-2 and more photo-stable and less pH sensitive. DAF-FM DA permeates well into living cells and is rapidly transformed into water-soluble DAF-FM by cytosolic esterases.
    		  
    • D2321   DAF-FM DA solution 5 mM in DMSO, ≥97% (HPLC) DAF-FM DA is a cell-permeable fluorescent probe for the detection of nitric oxide (NO). DAF-2 is the original compound and is widely used, but DAF-FM and DAF-FM DA are more sensitive to nitric oxide (NO) compared with DAF-2 and more photo-stable and less pH sensitive. DAF-FM DA permeates well into living cells and is rapidly transformed into water-soluble DAF-FM by cytosolic esterases.
    		  
    • D2196   DAF-FM solution 5 mM in DMSO, ≥97% (HPLC) DAF-FM is a highly sensitive, photo-stable fluorescent probe for the detection of nitric oxide (NO). DAF-2 is the original compound and is widely used, but DAF-FM is more sensitive to nitric oxide (NO) compared with DAF-2. DAF-FM (Ex: 500 nm; Em: 515 nm; dectection limit: 3 nM) is more photo-stable and less pH sensitive than DAF-2. DAF-FM is not quite as cell-permeable as the diacetate derivative, but it does not need to be activated by cytosolic enzymes.
    		  
    • SML2378 Dalbavancin ≥90% (HPLC) Dalbavancin is a semisynthetic, vancomycin class lipoglycopeptide with antibacterial activity against a variety of gram-positive pathogens, including methicillin-resistant S. aureus & S. epidermidis (MRSA & MRSE), but not gram-negative or vancomycin-resistant enterococci that possess VanA gene. Similar to vancomycin and other class members (e.g. teicoplanin, telavancin, ramoplanin, and ritavancin), dalbavancin disrupts bateria cell wall formation and cell membrane integrity by targeting the D-alanyl-D-alanyl residues on the growing peptidoglycan chains, blocking transpeptidation and peptidoglycan elongation.
    		  
    • SML2091 Dalcetrapib ≥97% (HPLC) Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. It increases HDL levels, but showed variable results on clinical outcomes. Clinical outcomes, effects on C-reactive protein and cholesterol efflux have been found to be genotype-dependent, influenced by correlated polymorphisms in the ADCY9 (adenylate cyclase type 9) gene. Positive results were obtained with AA genotype of ADCY9 gene whereas the GG genotype showed negative results and the AG genotype was neutral.
    		  
    • D7441 Daltroban >98% (HPLC) Selective thromboxane A2 receptor antagonist
    		 human ... TBXA2R(6915)
    • SML0255 4-DAMP ≥98% (HPLC) 4-DAMP is a M3 preferring cholinergic receptor antagonist.
    		  
    • D8399 Danazol ≥98% Danazol is a weak androgen; anterior pituitary suppressant.
    		  
    • SML0679 Danshensu sodium salt ≥98% (HPLC) Danshensu is an active component of Salvia miltiorrhiza (Danshen) that suppresses the formation of reactive oxygen species, inhibits platelet adhesion and aggregation, and protects myocardium against ischemia. Danshensu is cardioprotective, which protects myocardium from the reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation.
    		  
    • D9175 Dantrolene sodium salt Inhibitor of Ca2+ release from sarcoplasmic reticulum; muscle relaxant.
    		  
    • D3943 DAPH ≥98% (HPLC), solid DAPH is an inhibitor of Aβ fibril formation; Protein tyrosine kinase inhibitor, specific for EGFR.
    		 human ... EGFR(1956)
    • SML1610 Dapiprazole hydrochloride ≥98% (HPLC) Dapiprazole hydrochloride is an an α-adrenergic blocking agent that is used to reverse mydriasis after eye examination.
    		  
    • D7071 Dapoxetine hydrochloride ≥98% (HPLC) Potent Selective serotonin reuptake inhibitor (SSRI); used in treatment of premature ejaculation
    		  
    • D5942 DAPT ≥98% (HPLC), solid DAPT is a γ-secretase inhibitor and indirectly an inhibitor of Notch, a γ-secretase substrate. Other γ-secretase substrates include LDL receptor-related protein, E-cadherin and ErbB-4. As an inhibitor of γ-secretase, DAPT may be useful in the study of β-amyloid (Aβ) formation. DAPT has been shown to inhibit Notch signaling in studies of autoimmune and lymphoproliferative diseases, such as ALPS and lupus erythematosus (SLE), as well as in cancer cell growth, angiogenesis, and differentiation of human induced pluripotent stem cells (hIPSC).
    		 human ... APH1A(51107), APH1B(83464), NCSTN(23385), NOTCH1(4851), NOTCH2(4853), NOTCH3(4854), NOTCH4(4855), PSEN1(5663), PSEN2(5664), PSENEN(55851)
    mouse ... Aph1a(226548), Aph1b(208117), Ncstn(59287), Notch1(18128), Notch2(18129), Notch3(18131), Notch4(18132), Psen1(19164), Psen2(19165), Psenen(66340)
    rat ... Aph1a(365872), Aph1b(300802), Ncstn(289231), Notch1(25496), Notch2(29492), Notch3(56761), Notch4(406162), Psen1(29192), Psen2(81751), Psenen(292788)
    • SML0977 Darglitazone sodium salt ≥98% (HPLC) Darglitazone is a highly potent and selective PPAR-γ (peroxisome proliferator-activated receptor-γ) agonist. Darglitazone is a thiazolidinedione approximately 200x more potent than ciglitazone. Darglitazone restores euglycemia and reduced circulating TG and VLDL in the ob/ob mice. Also Darglitazone offers a significant neuroprotection and promotes recovery after a hypoxic-ischemic insult in the diabetic ob/ob mouse.
    		  
    • SML1102 Darifenacin hydrobromide ≥98% (HPLC) Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. Darifenacin hydrobromide has 9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4. Darifenacin is used clinically to treat urinary incontinence and overactive bladder syndrome.
    Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor.
    		  
    • SML0937 Darunavir ≥98% (HPLC) Darunavir has been sanctioned by the food and drug administration (FDA) as the first treatment of drug-resistant human immunodeficiency virus (HIV).
    Darunavir is a second-generation antiviral HIV protease inhibitor with broad spectrum activity.
    		  
    • SML0845 DAU-5884 ≥98% (HPLC) DAU-5884 is a M3-selective muscarinic receptor antagonist. The compound DAU-5884 blocks cobrotoxin-induced transient A-type K(+) currents in dorsal root ganglion neurons.
    		  
    • SML0597   Daurisoline ≥98% (HPLC) Daurisoline alkaloid isolated from the rhizomes of Menispermum dauricum that exhibit varies pharmacological activities including antiplatelet aggregation, anti-inflammatory, neuron-protective properties, and antiarrhythmic effect. It appears that antiarrhythmic effect of daurisoline is maintained through blockade of hERG channels.
    Daurisoline is antiarrythmic, anti-inflammatory, neuron-protective; and blocks hERG channels.
    		  
    • SML2063   Davunetide trifluoroacetate salt ≥95% (HPLC) Davunetide (NAPVSIPQ; NAP) is an eight amino acid peptide identified as the active component of activity-dependent neuroprotective protein (ADNP). It has been found to be neuro-protective at femtomolar concentrations in vitro against the neural toxicity of a wide range of compounds. Davunetide has been investigated for Parkinson′s disease and schizophrenia and in clinical trials for Alzheimner′s Disease, targeting microtubule-tau Interaction.
    		 
    • SML0031 DBeQ ≥98% (HPLC) DBeQ is a potent and specific inhibitor of ATPase p97, an integral component of the ubiquitin-fusion degradation (UFD) pathway. DBeQ inhibits the degradation of ubiquitinated proteins, the endoplasmic reticulum-associated degradation pathway, and autophagosome maturation. The compound also potently inhibits cellular proliferation and induces caspase 3/7 activity and apoptosis.
    		  
    • D7938 DBO-83 solid Novel nicotinic acetylcholine receptor agonist, structurally related to epibatidine, with antinociceptive properties in rodents.
    		 human ... CHRNA1(1134), CHRNA10(57053), CHRNA2(1135), CHRNA3(1136), CHRNA4(1137), CHRNA5(1138), CHRNA6(8973), CHRNA7(1139), CHRNA9(55584), CHRNB1(1140), CHRNB2(1141), CHRNB3(1142), CHRNB4(1143)
    • SML1512 DC_05 ≥98% (HPLC) DC_05 is a potent and selective non-nucleoside DNMT1 (DNA methyltransferase 1) inhibitor that significantly inhibits cancer cell proliferation.
    		  
    • SML1050   DC260126 ≥98% (HPLC) DC260126 is a FFA1 (GPR40) selective antagonist. In FFA1-expressing CHO cells, DC260126 blocks linoleic acid-induced Ca2+ elevation and ERK phosphorylation (IC50 = 6028 μM), as well as palmitic acid potentiated glucose-stimulated insulin secretion. The compound DC260126 blocks MIN6 β cells from palmitic acid-induced ER stress and apoptosis.
    		  
    • SML1640 DC_AC50 ≥98% (HPLC) DC_AC50 is an inhibitor of copper trafficking proteins Atox1 and CCS, resulting in a disruption of cellular copper transport. Cancer cells rely more heavily on Atox1 and CCS than normal cells. DC_AC50 blockade of copper trafficking induces cellular oxidative stress, affecting cancer cells more strongly than normal cells, and leading to the inhibition of cancer cell proliferation.
    		  
    • SML1714 DCAI ≥95% (HPLC) DCAI, an Inactive Ras, is bound to a GDP and activated by SOS (son of sevenless, among others), which converts it to the active GTP form. DCAI is a known binder to Ras, which inhibits SOS nucleotide exchange, inhibiting Ras activation.
    		  
    • SML0515 DCAP ≥95% (HPLC) DCAP is a potent broad-spectrum antibiotic that specifically targets the membranes of both Gram-positive and Gram-negative bacteria. It reduces the transmembrane potential, kills stationary-phase cells and sterilizes bacterial biofilms. DCAP has no effect on red blood cell membranes at levels toxic to bacteria.
    		  
    • D1068 DCB ≥98% (HPLC), solid 3,3′-dichlorobenzaldazine (DCB) serves as an allosteric ligand with neutral cooperativity. It helps to block the positive allosteric regulation of mGluRs (metabotropic glutamate receptor subtype 5 (mGluR5) with the help of 3,3′-difluorobenzaldazine (DFB) and the negative modulatory effect of 3,3′-dimethoxybenzaldazine (DMeOB).
    Neutral allosteric modulator of the metabotropic glutamate receptor mGluR5.
    		  
    • D9190 DCEBIO ≥98% (HPLC), solid DCEBIO facilitates Cl− secretion in the epithelia by activating K+ and Cl− currents.
    		 human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363)
    • D5569 DCHC ≥98% (HPLC), solid DCHC is a SIRT1 activator. It increases peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) expression, resulting in mitochondrial biogenesis. DCHC activates SIRT1 at low micromolar concentrations (5–10 μM) and increases SIRT1 activity at 100 μM. It is different from 5,7,4′-T in that it induces the activation of recombinant SIRT1, but does not increase SIRT1 expression.
    		  
    • D5318 DCP-LA ≥95% (HPLC), oil DCP-LA is a selective PKC-epsilon (PKC-ε) activator. In the in situ PKC assay with a reversed phase high-performance liquid chromatography, DCP-LA significantly activated PKC in PC-12 cells in a concentration (10 nM-100 μM)-dependent manner, with the maximal effect at 100 nM. DCP-LA has over a 7-fold greater potency for activation of PKC-ε over other PKC isozymes.
    		  
    • SML0490 DDN ≥98% (HPLC) DDN (5,8-Diacetyloxy-2,3-dichloro-1,4-naphthoquinone) is a selective insulin receptor (IR) activator that binds directly to the receptor kinase domain and induces the Akt and ERK phosphorylations. DDN also improves glucose uptake in adipocytes and produces oral hypoglycemic effect in wild-type and diabetic mice models.
    		  
    • SML2274 DDR1-IN-1 ≥98% (HPLC) DDR1-IN-1 is a type II, subtype-selective discoidin domain receptor (DDR) tyrosine kinase inhibitor (DDR1/2 IC50 = 105 nM/413 nM) that effectively blocks collagen-induced DDR1 pY513 autophosphorylation in U2OS cells (EC50 = 86.76 nM) with excellent selectivity over a panel of >380 kinases. DDR1-IN-1 inhibits DDR2-mediated MT1-MMP activation in human rheumatoid synovial fibroblasts (RASF) upon collagen stimulation (IC50 < 2.5 μM) and enhances PI3K/mTOR inhibitor GSK2126458 antiproliferation efficacy in SNU-1040 colorectal cancer culture (123%, 70%, 50% of control, respectively, post 48-hr 250 nM DDR1-IN-1, 82.5 nM GSK2126458, or combined treatment). ent). ned treatment).
    DDR1-IN-1 protects cells from apoptosis by inhibiting collagen-mediated Bcl-2-interacting killer (BIK) induction at both mRNA and protein levels.
    		  
    • SML1832 DDR1 Inhibitor 7rh ≥98% (HPLC) DDR1 Inhibitor 7rh is an orally available, potent, ATP-competitive DDR1-selective inhibitor with in vitro and in vivo anti-cancer efficacy.
    Compound 7rh is a potent, high affinity (Kd =0.6 nM), ATP-competitive inhibitor against discoidin domain-containing receptor 1 (DDR1; IC50 = 6.8 nM, [ATP] = 100 nM) with significantly reduced potency toward 455 other kinases, including DDR2, Bcr-abl, and c-Kit (IC50 = 101.4 nM, 355 nM and >10 μM, respectively). Inhibitor 7rh reduces DDR1 expression/phosphorylation and downstream signaling in a dose-dependent manner (0.1-2 μM; NCI-H23 NSCLCs), effectively suppressing human cancer cells proliferation (IC50 from 38 nM/K562 to 2.98 μM/NCI-H460) and colony formation (IC50 = 0.56 μM/NCI-H23). Inhibitor 7rh is orally availabe in rats and mice (T1/2 = 15.53 h; Tmax = 4.25 h; Cmax = 1867.5 μg/L, F = 67.4%; 25 mg/kg; rats) and displays in vivo efficacy against Kras (LSLG12Vgeo) tumor growth in mice (50 mg/kg/day p.o.).
    		  
    • SML0710 DDRI-18 ≥98% (HPLC) DDRI-18 (DNA Damage Response Inhibitor-18) inhibits nonhomologous end-joining (NHEJ) DNA repair following double strand DNA breaks induced by ionizing radiation, and enhances the effects of DNA-damaging cancer drugs like etoposide, camptothecin and doxorubicin.
    		  
    • D8296 3-Deazaadenosine Possesses antiviral activity inhibitor of leukocyte adhesion to TNF-treated endothelial cells.
    		 rat ... Adora1(29290), Adora2a(25369), Adora3(25370)
    • SML0305 3-Deazaneplanocin A hydrochloride ≥97% (HPLC) 3-Deazaneplanocin A (DZNep) is an S-Adenosylhomocysteine Hydrolase inhibitor and histone methyltransferase EZH2 inhibitor. It switches on repressed tumor suppressor genes and induces apoptosis by inhibiting the expression of EZH2.
    		  
    • D1260 Decamethonium bromide crystalline Decamethonium serves as a muscle relaxant and is also a neuromuscular blocking agent. It has a molecular weight of 258.4.
    Nicotinic acetylcholine receptor partial agonist and neuromuscular blocking agent; depolarizes striated muscles and blocks their activity.
    		 human ... CHRNA1(1134), CHRNA10(57053), CHRNA2(1135), CHRNA3(1136), CHRNA4(1137), CHRNA5(1138), CHRNA6(8973), CHRNA7(1139), CHRNA9(55584), CHRNB1(1140), CHRNB2(1141), CHRNB3(1142), CHRNB4(1143)
    • SML0786   Decursin ≥97% (HPLC) Decursin is a cumarin isolated from Radix peucedani that exhibits a number of physiological actions including anticancer, antibacterial, antinematodal and antioxidant. Decursin is potent anti-angiogenic agent targeting the VEGFR-2 signaling pathway. Decursin exhibits potent neuroprotective activity against glutamate and Ab- induced neurotoxicity. Apparently, decursin stimulates activation of Nerf2. Also, decursin inhibits androgen stimulated AR translocation to the nucleus in LNCaP prostate cancer cells.
    		  
    • SML0123 Deflazacort ≥98% (HPLC) Deflazacort is an anti-inflammatory and immunosuppressant glucocorticoid.
    		  
    • D0817 (−)-Deguelin >98% (HPLC), powder Inhibitor of activated Akt. Does not affect MAPK, ERK1/2, or JNK. Anticancer, chemoprotective agent.
    		  
    • D2154 5,6-Dehydroarachidonic acid ≥98%, ethanol solution Inhibits 5-lipoxygenase of guinea pig leukocytes with an IC50 of 10 μM. In extracts of rat basophilic leukemia cells preincubated with 5,6-dehydro AA, the Ki for the conversion of arachidonic acid to 5-HPETE is 15 μM.
    		  
    • D5297 Dehydroisoandrosterone 3-sulfate sodium salt dihydrate ≥93% (TLC), powder Dehydroisoandrosterone 3-sulfate sodium salt dihydrate is a negative allosteric modulator of GABAA receptors.
    		 human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562)
    • D4196 Dehydroleucodine ≥98% (HPLC) Dehydroleucodine is a sesquiterpene lactone isolated from Artemisia douglasiana Besser; mast cell stabilizers. An extract from the plant is widely used in Cuyo region (Argentina) as folk medicine for the treatment of gastric ailments. The compound prevents gastric and duodenal damages in response to necrosis-inducing agents. Stabilization of mast cells may be a key mechanism to protect the gastrointestinal tract from injury and ulceration. Recently, it was established that dehydroleucodine and xanthatin inhibit mast cell degranulation induced by compound 48/80.
    		 
    • D4875 16-Dehydropregnenolone acetate ≥95% 16-Dehydropregnenolone acetate (DPA) is synthesized from steroids sapogenin, diosgenin and solasodine. 16-Dehydropregnenolone acetate (DPA) is a crucial intermediate for the synthesis of steroid hormones-based drugs. It is an antagonist for farnesoid X receptor (FXR) and modulates cholesterol metabolism. It is considered as a potential antihyperlipidemic agent. Chemically synthesized steroid derivatives from DPA have cytotoxic features and could serve as potential anticancer agents.
    		  
    • SML1679 DEL-22379 ≥98% (HPLC) DEL-22379 is a cell-permeable 3-arylidene-2-oxindole derivative that inhibits the dimerization of ERK (IC50 = 500 nM) via directly binding to its dimerization interface. DEL-22379 promotes the transactivation of ELK, and prevents the EGF-induced phosphorylation of the cytoplasmic kinase RSK1 in HEK293 cells (IC50 = 500 nM). DEL-22379 induces apoptosis in various cancer cells harboring RAS-ERK pathway oncogenes (IC50 = 150 – 400 nM). DEL-22379 blocks tumor progression and metastasis in multiple xenograft models such as A375 (BRAF mutant), HCT116 (KRAS mutant) and colorectal cancer patient-derived xenografts (15 mg/kg, i.p. b.i.d.).
    		 
    • SML1869 Delafloxacin ≥98% (HPLC) Delafloxacin is a fluoroquinolone antibiotic active against both Gram-negative and Gram-positive bacteria such as MRSA. Delafloxacin targets both DNA gyrase and topoisomerase IV, inhibiting DNA synthesis. Unlike most fluoroquinolones, delafloxacin is weakly acidic, which increases its potency in an acidic environments such as those existing in inflammatory cells and in skin and soft tissue infections. Delafloxacin shows good activity against most fluoroquinolone-resistant strains.
    Delafloxacin is mostly prefered for the treatment of respiratory tract infections.
    		  
    • PZ0180 Delavirdine mesylate ≥98% (HPLC) Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1.
    		  
    • SML2154 Deltarasin trihydrochloride ≥98% (HPLC) Deltarasin is a membrane-permeable benzimidazole derivative that effectively abolishes cellular KRas plasma membrane localization (5 μM for 1 hr) by blocking KRas-PDEδ interaction via high affinity interaction with PDEδ prenyl-binding pocket (KD = 38 nM). Deltarasin inhibits oncogenic KRas-dependent proliferation (by ~50% of Panc-Tu-I cells; 5μM for 70 hrs) and survival (52% and 46% death induction of Panc-Tu-I and Capan-1 cells, respectively; 5μM for 24 hrs) in human pancreatic ductal adenocarcinoma (PDAC) cultures and is efficacious against Panc-Tu-I xenograft-derived tumor growth in mice in vivo (60% and 80% retardation on day 9, respectively, with 15 mg/kg q.d. or 10 mg/kg b.i.d. via i.p.).
    		  
    • D7696 Demethoxycurcumin ≥98% (HPLC) Demethoxycurcumin (DMC) is a derivative or curcumin, and represents one of the major active components of curcumin products isolated from Curcumae sp. DMC inhibits LPS-induced nitric oxide (NO) production, and expression of iNOS and COX2 in RAW264.7 cells by blocking NF-kB activation. DMC also inhibits NF-kB dependent iNOS, TNFα and IL-1β expression in LPS-treated rat microglial cells. DMC suppresses expression of MMPs and ICAM-1 in MDA-MB-231 human breast cancer cells by inhibition of NF-kB.
    		  
    • D6189   Dendroaspis Natriuretic Peptide trifluoroacetate salt ≥90% (HPLC) Structural homolog of natiuretic peptides containing a 17 amino acid disulfide ring similar to ANP, BNP, and CNP that mediate their physiological effects through particulate guanylyl cyclase receptors generating cGMP.
    		  
    • D4438   β-Dendrotoxin ≥98% (SDS-PAGE), lyophilized powder    
    • D4813 Dendrotoxin-K ≥98% (HPLC), lyophilized powder Dendrotoxin-K inhibits potassium channels that contain Kv1.1 protein only.
    		  
    • D7815 R(−)-Denopamine ≥98% (HPLC), powder β1-adrenoceptor agonist.
    		 human ... ADRB1(153)
    • D7000 Deoxycorticosterone acetate    
    • P9521 21-Deoxycortisol 21-Deoxycortisol is a 17-hydroxyprogesterone derivative. It serves as a marker for congenital adrenal hyperplasia, an autosomal recessive disorder, indicated by 21-hydroxylase deficiency.
    		  
    • D0156 Deoxynivalenol    
    • D8440 15-Deoxy-Δ12,14-prostaglandin J2 ≥95% (HPLC), 1 mg/mL in methyl acetate Selective agonist to PPARγ (peroxisome proliferator-activated receptors). Inhibits the proliferation of cancer cell lines that express PPARγ and cyclooxygenase-2 (COX-2).
    		  
    • M003 R-(−)-Deprenyl hydrochloride powder, ≥98% (HPLC) Selective MAO-B inhibitor; anti-Parkinsonian agent.
    		 human ... MAOB(4129)
    • D3768 Dequalinium chloride hydrate ≥95% (titration) Dequalinium chloride is a selective blocker of apamin-sensitive K+ channels and inhibitor of XIAP (X-linked inhibitor of apoptosis protein). Has been shown to induce cytotoxicity in human acute promyelocytic leukemia NB4 cells through disturbance of mitochondrial function, oxidative stress, and downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways.
    		  
    • SML2014   Deracoxib ≥98% (HPLC) Deracoxib is an orally active cyclooxygenase-2 (COX-2) inhibitor with >48-fold selectivity over COX-1 (IC50 of 203-189 nM against COX-2-dependent PGE2 production vs. IC50 of 9.85-9.96 μM against COX-1-dependent TxB2 production in dog whole blood). Deracoxib is also reported to exhibit inhibitory activity against phosphodiesterase (Ki = 3.6 μM against human PDE4D3) as well as positive modulatory effiacy toward 2-APB-stimulated transient receptor potential vanilloid 3 channel (TRPV3) activity.
    		  
    • SML0829   Dermorphin trifluoroacetate salt ≥98% (HPLC) Dermorphin is a natural opioid originally isolated from the skin of South American frogs Dermophin has high selectivity as a μ-Opioid receptor (MOR) agonist and is 30–40 times more potent than morphine.
    		  
    • SML1289 Desferrithiocin sodium salt ≥98% (HPLC) Desferrithiocin is an iron chelator.
    		  
    • SML0649   Deshydroxy LY-411575 ≥98% (HPLC) Deshydroxy LY-411575 is a cell-permeable γ-secretase inhibitor and inhibtor of Notch processing. Deshydroxy LY-411575 significantly lowers both brain and plasma Aβ40 levels by ~72% in Tg2576 mutant APP transgenic mouse model and potently blocks Notch processing, with an IC50 of 1.7 nM in SupT1 cells.
    LY411575 prevents SPP (signal peptide peptidase) dependent cleavage of HCV (hepatitis C virus) core protein.
    		  
    • D3900 Desipramine hydrochloride ≥98% (TLC), powder Tricyclic antidepressant that is a more potent inhibitor of the norepinephrine transporter (Ki = 4 nM) than the serotonin transporter (Ki = 61 nM).
    		  
    • D5676 N-Desmethylclozapine Major metabolite of clozapine; potent 5-HT2 serotonin receptor antagonist and a ligand for the cloned 5-HT6 and 5-HT7 serotonin receptors. Also an allosteric potentiator of M1 muscarinic receptors.
    N-Desmethylclozapine serves as an agonist to muscarinic acetylcholine receptors, and is known to exert its antipsychotic action. It blocks synaptic transmission by antagonizing synaptic GABA (γ-aminobutyric acid) receptors.
    		 human ... KCNH1(3756)
    • UC305 O-Desmethylnaproxen CYP2C9 metabolite of naproxen
    		  
    • D204 S-(+)-O-Desmethylraclopride hydrobromide solid, ≥98% (HPLC)    
    • D9069 N-Desmethyltamoxifen HCl ≥98% (HPLC), solid N-Desmethyltamoxifen HCl is the primary metabolite of tamoxifen. N-Desmethyltamoxifen HCl is an estrogen response modifer and protein kinase C inhibitor.
    		  
    • UC304 O-Desmethyltramadol Metabolite of tramadol
    		  
    • D6513 Desmosterol ≥84% (GC)    
    • D2069 Desvenlafaxine hydrochloride ≥98% (HPLC), powder Desvenlafaxine hydrochloride is a dual SERT/NET reuptake inhibitor. It is a major active metabolite of venlafaxine (#542); brain penetrant; Ki = 40 nM and 122 nM for hSERT and hNET, respectively (weak binding at the hDAT). Inhibition of [3H]5-HT or [3H]NE uptake for the hSERT or hNET produced IC50 values of 47 and 531 nM.
    		  
    • D3821 Devazepide ≥98% (HPLC), powder Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.
    Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine.
    		  
    • D1756 Dexamethasone ≥98% (HPLC), powder Dexamethasone is known to be effective against relapsed multiple myeloma. It is found to decrease inflammation associated with cerebrospinal fluid and central nervous system (CNS) complications, such as hearing loss.
    Glucocorticoid anti-inflammatory agent. Regulates T cell survival, growth, and differentiation. Inhibits the induction of nitric oxide synthase.
    		 human ... ABCB1(5243), CYP3A4(1576), IL4(3565), IL5(3567), NR3C1(2908)
    mouse ... Abcb1a(18671), Abcb1b(18669), Ifng(15978), Nos2(18126), Ptgs2(19225), Tnf(21926)
    rat ... Ar(24208), Nr3c1(24413), Tnf(24835)
    • D1881 Dexamethasone 21-acetate ≥99% An anti-inflammatory glucocorticoid.
    		  
    • SML0956   Dexmedetomidine hydrochloride ≥98% (HPLC) Dexmedetomidine hydrochloride is a highly potent and selective α2-adrenergic agonist with analgesic and sedative properties, the (+)-isomer of medetomidine. Dexmedetomidine hydrochloride is used clinically as an anesthetic agent to reduce anxiety and tension and promote relaxation and sedation without causing respiratory depression.
    		  
    • SML0392 Dexpramipexole dihydrochloride ≥98% (HPLC) R-(+)-Pramipexole is a neuroprotective agent; weak non-ergoline dopamine agonist. R-(+)-Pramipexole has been found to have neuroprotective effects and is being investigated for treatment of ALS. It reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, R-(+)-Pramipexole has much lower dopamine agonist activity.
    		  
    • D1446 Dexrazoxane ≥95% (HPLC) Dexrazoxane is a cardioprotective compound against anthracyclines. It functions by inhibiting topoisomerase II without inducing DNA strand breaks. Dexrazoxane is a + enantiomer of razoxane.
    		  
    • D2531 Dextromethorphan hydrobromide monohydrate ≥99% (TLC) Dextromethorphan hydrobromide is an allosteric antagonist at N-methyl D- aspartate (NMDA)-controlled ion channels and antagonist at voltage-dependent channels. Dextromethorphan hydrobromide is useful in treating dry cough.
    		 human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRIN3A(116443), GRIN3B(116444)
    • UC205 Dextrorphan   human ... GRIN2A(2903)
    rat ... Grin2a(24409)
    • SML1627 DFHBI 3,5-difluoro-4-hydroxybenzylidene imidazolinone (DFHBI) is non fluorescent when unbound.
    DFHBI is a membrane permeable and nontoxic fluorogen, which produces fluorescence upon binding. RNA aptamers Spinach, Spinach2 and Broccoli. DFHBI displays fluorescence excitation maxima of 447 nm and peak fluorescence emission of 501 nm. DFHBI is used for imaging RNA in cells.
    		  
    • SML0994   DFU ≥98% (HPLC) DFU is an orally available highly selective cyclo-oxygenase-2 (COX-2) inhibitor that potently inhibits lipopolysaccharide (LPS)-induced PGE2 production in a human whole blood assay.
    		  
    • SML1642 DHED ≥98% (HPLC) DHED (10β,17β-dihydroxyestra-1,4-dien-3-one) is an inactive prodrug that selectively produces estrogen solely in the brain. DHED is converted to 17β-estradiol in the brain by an enzyme only expressed in the CNS, but is inert in the rest of the body. DHED was found to provide neuroprotection in a rat stroke model and reversed neurological symptoms of estrogen deprivation such as memory problems in female rats lacking ovaries.
    		  
    • D5919 Diacylglycerol Kinase Inhibitor I solid Diacylglycerol kinase inhibitor. Inhibits formation of [38P]1-Oleoxyl-2-acetylglyceryl-3-phosphoric acid (OAPA) in red blood cell membranes: IC50 = 3.3 μM.
    		  
    • D5794 Diacylglycerol Kinase Inhibitor II solid Diacylglycerol kinase inhibitor. Inhibits formation of [38P]1-Oleoyl-2-acetylglyceryl-3-phosphoric acid (OAPA) in red blood cell membranes: IC50 = 3.3 μM.
    		  
    • P7769 1,2-Diacyl-sn-glycero-3-phospho-L-serine ≥97% (TLC), from bovine brain, amorphous powder 1,2-Diacyl-sn-glycero-3-phospho-L-serine or phosphatidylserine (PS) is a structurally diverse acidic phospholipid having fatty acid ester at the glycerol sn positions. Bovine brain cortex based PS is a potent brain nutrient. It favors neurotransmission and may improve memory in dementia. PS is also the major membrane phospholipid associated with the nuclear membrane, myelin, endoplasmic reticulum, Golgi and mitochondria. The synthesis of PS is catalyzed by phosphatidylserine synthase 1 from L-serine and CDP-diacylglycerol in the mitochondria-associated membrane (MAM) domains of the endoplasmic reticulum. PS is externalized during phagocytosis and is dysregulated in tumors making it a potential marker for therapeutic targeting.
    A slowly metabolized structural phospholipid found mainly in gray matter.
    		  
    • D1262 P1,P4-Di(adenosine-5′) tetraphosphate ammonium salt ≥95% (HPLC), powder Diadenosine polyphosphate functions as a second messenger in pancreatic cells, stimulates phospholipase D, changes intracellular calcium levels, induces nitric oxide release, activates 5′-nucleotidase, and inhibits adenosine kinase activity in vitro.
    Diadenosine polyphosphate is stored in secretory granules of thrombocytes, chromaffin, and neuronal cells. After release into the extracellular space, it affects a variety of biological activities in a wide range of target tissues. It appears to function as a second messenger in pancreatic cells. In rat liver cells. it stimulates phospholipase D and changes intracellular calcium levels. It has been shown to induce nitric oxide release from endothelial cells. In the nervous system it acts through various purinoceptors. It also activates 5′-nucleotidase and inhibits adenosine kinase activity in vitro. Ap4A is metabolized by soluble enzymes in the blood plasma and by membrane-bound ectoenzymes of a number of cell types including endothelial cells, smooth muscle cell.
    		 human ... PLD1(5337), PLD2(5338), PLD3(23646), PLD4(122618), PLD5(200150)
    • P4394 cis-Diammineplatinum(II) dichloride crystalline Potent chemoimmunotherapeutic drug; stimulates the immune responses by activating macrophages and other cells of the immune system. Cisplatin-treated macrophages show increased antigen presentation function in vitro. Treatment increased cellular NF-κB content and translocation in macrophages. Cisplatin effects are regulated by kinases, phosphatases, and Ca2+/calmodulin. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand crosslinks.
    Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.
    		  
    • SML0927   Diapocynin ≥98% (HPLC) Diapocynin is a covalent dimer of apocynin, and a functional metabolite of the same. It is generated by neutrophil activation via myeloperoxidase-mediated oxidation. Studies show that diapocynin has greater neuroprotection compared to apocynin.
    Diapocynin, a proposed NADPH oxidase (NOX) inhibitor, is an anti-inflammatory and antioxidant agent. Diapocynin attenuates oxidative damage and neuroinflammatory responses in animal model of Parkinson’s disease. Diapocynin reverses deficient motor coordination in LRRK2R1441Gtg mice of PD.
    		  
    • D0899 Diazepam Diazepam is a benzodiazepine anxiolytic agent. It serves as a prototype ligand for the GABAA receptor benzodiazepine modulatory site.
    Diazepam is often used as a sedative. Its metabolism involves cytochrome P450 (CYP) 2C19 and 3A4. Diazepam has immediate action upon administration.
    		 human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA5(2558), GABRA6(2559)
    rat ... Gabra1(29705), Gabra2(29706)
    • D9035 Diazoxide Selective ATP-sensitive K+ channel activator in both vascular smooth muscle and pancreatic β-cells; antihypertensive.
    		 human ... KCNA1(3736), KCNJ11(3767), KCNMA1(3778)
    mouse ... Kcnj1(56379), Kcnj11(16514)
    rat ... Gria1(50592), Kcna1(24520), Kcnj1(24521), Kcnj11(83535), Kcnj8(25472)
    • W0641 W-84 dibromide ≥98% (HPLC), solid Potent allosteric modulator of M2 muscarinic acetylcholine receptors.
    		  
    • D0260 N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt ≥97% (HPLC), powder Cell-permeable cAMP analog that activates cAMP dependent protein kinase (PKA).
    		  
    • D8190 3′,4′-Dichlorobenzamil hydrochloride >98% (HPLC) Inhibits Na+/Ca2+ exchanger, Na+ transport and sarcoplasmic reticulum Ca2+ release channels.
    		  
    • D1916 5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside 5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB), a nucleoside analog that halts mRNA synthesis by phosphorylation of the C-terminal domain of RNA polymerase II, making it inactive. It also interferes with the DNA topoisomerase II, may modulate response to cytokines and blocks the human immunodeficiency virus (HIV) via RNA modification. It also inhibits cyclin-dependent kinases (CDKs) 7 and 9 and favors apoptosis in leukemic cells. It may serve as a therapeutic agent in treating cancer.
    Inhibitor of RNA synthesis; causes premature termination of transcription. CK2 (casein kinase-2) inhibitor.
    		 human ... CSNK2A1(1457), CSNK2B(1460)
    • D6883 2′,7′-Dichlorofluorescin diacetate ≥97%    
    • D4434 Dichloromethylenediphosphonic acid disodium salt Analog of pyrophosphate ion that inhibits the osteoclastic activity leading to bone resorption and osteoporosis. The compound is used in cancer research, especially in skeletal metastases and breast carcinoma. When entrapped in liposomes, it is used for macrophage-selective depletion (macrophage "suicide" technique), especially in spleen and liver. Found also to inhibit collagenase and matrix metalloproteinase1.
    		 rat ... Man2a1(25478), Si(497756)
    • D6899 Diclofenac sodium salt Diclofenac sodium salt is a nonsteroidal anti-inflammatory drug (NSAID) that acts as a competitive and irreversible inhibitor of prostaglandin synthetase. Its analgesic and anti-inflammatory activities are based on the prevention of the synthesis of arachinodate metabolites via cyclooxygenase inhibition. It is found to hinder the conversion of arachidonic acid to prostaglandins, which mediate inflammatory process. The NSAIDs are found to inhibit both cyclooxygenase enzymes, COX-1 and COX-2, causing undesirable gastrointestinal effect. Diclofenac sodium also functions as a scavenger of free radicals and serves a radioprotective role in restoring supercoiled form of plasmid DNA damaged by radiation back to normal. Diclofenac sodium is oxidized by the donation of electron and transfer of hydrogen atom. It can be a potential radioprotective agent.
    Standard NSAID and cyclooxygenase (COX) inhibitor. Major metabolites are 4´-hydroxydiclofenac and 5´-hydroxydiclofenac. Has been used as substrate selective for CYP2C9.
    		 human ... PTGS1(5742)
    • D7909 Dicyclomine hydrochloride ≥99% (TLC), powder Competitive muscarinic acetylcholine receptor antagonist.
    		 human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)
    • D1413 2′,3′-Didehydro-3′-deoxythymidine ≥98% (TLC) 2′,3′-Didehydro-3′-deoxythymidine is a nucleoside analog, which inhibits HIV replication in vitro. Stavudine has the ability to enter the cells by non-facilitated diffusion. It possesses inhibitory activity against moloney murine leukemia virus, friend murine leukemia virus and simian immunodeficiency virus.
    		  
    • D7408 2′,5′-Dideoxyadenosine ≥95% (HPLC), solid Cell-permeable adenylyl cyclase inhibitor. IC50 = 2.7 μM in detergent-dispersed rat brain preparations.
    		 rat ... Adcy2(81636)
    • D0939 2′,5′-Dideoxyadenosine 3′-triphosphate tetrasodium salt >91% (HPLC) Potent inhibitor of adenylyl cyclase. Not cell-permeable. IC50 = 40 nM in detergent-dispersed rat brain preparation.
    		  
    • D8174 9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α solution, 10 mg/mL in methyl acetate Thromboxane receptor agonist.
    		  
    • D0400 9,11-Dideoxy-9α,11α-epoxymethanoprostaglandin F2α Prostaglandin F2α analogue; thromboxane A2/prostaglandin H2 mimetic.
    		  
    • D3658 1,9-Dideoxyforskolin from Coleus forskohlii ≥97%, solid Biologically inactive forskolin analog. Does not stimulate adenylyl cyclase.
    		  
    • SML2035 Didox ≥98% (HPLC) Didox is a ribonucleotide reductase (RNR) inhibitor that inhibits proliferation of and decreased secretion of cytokines IL-6, IFN-g, TNF-a, IL-2, IL-13, IL-10 and IL-4. Didox inhibits proliferation of tamoxifen-resistant breast cancer cells. Didox is an antioxidant that potentiates the cytotoxic profile of doxorubicin.
    		 
    • SML1468 Dienogest ≥98% (HPLC) Dienogest is a fourth-generation progestin, an orally active synthetic progestogen with approximately 10% of the relative affinity of progesterone, but has a very potent progestagenic effect in the endometrium with some antiandrogenic activity and without any androgenic, glucocorticoid or mineralocorticoid effects. It has been used alone or in combination as a contraceptive and to treat uterine fibroids. Dienogest inhibits ovulation primarily through peripheral action rather than by central action on gonadotrophin secretion.
    		  
    • D184 Diethylamine NONOate sodium salt hydrate ≥97% (NMR) Diethylamine NONOate is a complex of diethylamine with nitric oxide used to generate a controlled release of nitric oxide in solution.
    		  
    • D185 Diethylenetriamine/nitric oxide adduct ≥97% (NMR), solid    
    • D4628 Diethylstilbestrol ≥99% (HPLC) Diethylstilbestrol is a synthetic estrogen with carcinogenic properties. Causes renal clear-cell carcinoma in Syrian hamster. In humans it causes increased risk of breast cancer, clear cell adenocarcinoma (CCA) of the vagina and cervix, and reproductive anomalies. Used in the treatment of prostate cancer to block the production of testosterone.
    		 human ... ESR1(2099), ESR2(2100), ESRRG(2104)
    mouse ... Esr1(13982)
    rat ... Ar(24208), Esr1(24890)
    • D7692 Diethylumbelliferyl phosphate ≥98% (HPLC), oil Diethylumbelliferyl phosphate is a selective, potent cholesterol esterase inhibitor. It blocks steroidogenesis primarily by preventing cholesterol transport into the mitochondria of steroidogenic cells. Inhibitors of cholesterol esterase are anticipated to limit the absorption of dietary cholesterol. IC50 = 11.6 μM.
    		  
    • SML0599   DIF-1 ≥98% (HPLC) DIF-1 (differentiation-inducing factor-1) is isolated from a Dictyostelium slime mold, and is used to inhibit proliferation/promote differentiation in various cell lines.
    DIF-1 is a cell differentiation inducing factor.
    Differentiation-inducing factor-1 (DIF-1) blocks the migration and invasion of cells and decreases the expression of matrix metalloproteinase-2. It prevents the proliferation of cells using glycogen synthase kinase-3 (GSK-3)-dependent mechanism. DIF-1 is more active when compared to DIF-2 in promoting stalk cell differentiation under submerged assay conditions.
    		  
    • D0567 DIF-3 ≥99% (HPLC), solid DIF-3 Inhibits cell cycle by inducing G0/G1 arrest.
    		  
    • D193 DL-α-Difluoromethylornithine hydrochloride hydrate solid, ≥97% (NMR) Difluoromethylornithine (Eflornithine) inhibits polyamine biosynthesis by the selective, irreversible inhibition of ornithine decarboxylase (ODC). A chemoprotective agent that blocks angiogenesis.
    		 human ... ODC1(4953)
    • D8941 2,6-Difluoro-4-[2-(phenylsul­fonyl­amino)­ethyl­thio]­phenoxy­acet­amide ≥98% (HPLC), solid 2,6-Difluoro-4-[2-(phenylsul­fonyl­amino)­ethyl­thio]­phenoxy­acet­amide is a structurally novel, selective, high affinity AMPA ionotropic glutamate receptor agonist that reduces ischemia-induced performance deficits in rats.
    		 human ... GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893)
    • D6288 6α,9α-Difluoroprednisolone 21-acetate 17-butyrate ≥98%    
    • SML1976 DIM-C-pPhCO2Me ≥98% (HPLC) DIM-C-pPhCO2Me is a NR4A1 (Nur77) antagonist that exhibit potent anticancer activity in pancreatic, colon, breast, kidney, and rhabdomyosarcoma cells. DIM-C-pPhCO2Me decreases expression of PAX3-FOXO1A and β1-integrin proteins in Rh30 rhabdomyosarcoma and MDA-MB-231 breast cancer cells. DIM-C-pPhCO2Me inhibits migration of Rh30 and MDA-MB-231 cancer cells.
    DIM-C-pPhCO2Me is also known as 1,1-bis(3′-indolyl)-1-(p-carboxymethylphenyl)methane. In pancreatic and colon cancer cells, DIM-C-pPhCO2Me plays an inhibitory role on cell migration. DIM-C-pPhCO2Me prevents the action of mechanistic target of rapamycin (mTOR) and reduces the multiplication and survival of cancer cells. It stimulates reactive oxygen species (ROS) in various cancer cell lines.
    		  
    • SML1220 Doripenem hydrate ≥98% (HPLC) Doripenem hydrate is used to treat complicated urinary infection including Pyelonephritis caused by E.coli. Doripenem hydrate is promoted in the United States as DORIBAX®. This drug is synthesized from p-nitrobenzyl-protected enolphosphate 2b and N-(p-nitrobenzyloxycarbonyl)-protected aminomethylpyrrolidine.
    Doripenem is an ultra-broad spectrum carbopenem antibiotic. Doripenem is active against both gram-positive and gram-negative bacteria.
    		  
    • SML2191 D-Moses ≥98% (HPLC) D-Moses is a negative control to L-Moses a cell penetrant, potent and selective PCAF bromodomain (Brd) inhibitor.
    		  
    • SML2358 D-NMAPPD ≥98% (HPLC) D-NMAPPD (B13), a myristoyl-CoA analog, is a cell penetrant inhibitor of N-myristoyltransferases that suppressed FRS2α (fibroblast growth factor receptor substrate 2) myristoylation. D-NMAPPD inhibits wild-type FGFRs and drug-resistant mutants (FGFRsDRM) oncogenic signaling in cancer cells. D-NMAPPD potently inhibits growth of xenograft tumors in mice. D-NMAPPD is a potent inhibitor of ceramidase that elevates endogenous ceramide levels and suppress growth of cancer cells.